These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

841 related items for PubMed ID: 18322994

  • 1. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 4. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
    Wessels JA, Kooloos WM, De Jonge R, De Vries-Bouwstra JK, Allaart CF, Linssen A, Collee G, De Sonnaville P, Lindemans J, Huizinga TW, Guchelaar HJ.
    Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
    Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ.
    Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
    [Abstract] [Full Text] [Related]

  • 6. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [Abstract] [Full Text] [Related]

  • 7. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
    Schipper LG, Fransen J, Barrera P, Van Riel PL.
    Rheumatology (Oxford); 2009 Jul; 48(7):828-33. PubMed ID: 19458163
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
    Lie E, Uhlig T, van der Heijde D, Rødevand E, Kalstad S, Kaufmann C, Mikkelsen K, Kvien TK.
    Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
    [Abstract] [Full Text] [Related]

  • 9. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Apr; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 10. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M, Rudas T, Pawlik A, Gornik W, Kurzawski M, Herczynska M.
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [Abstract] [Full Text] [Related]

  • 11. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
    Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, Assaraf YG, Dijkmans BA.
    Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
    [Abstract] [Full Text] [Related]

  • 12. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y, Abou Atta I, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A.
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [Abstract] [Full Text] [Related]

  • 13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 14. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH.
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
    Schipper LG, Fransen J, Barrera P, den Broeder AA, Van Riel PL.
    Rheumatology (Oxford); 2009 Oct; 48(10):1247-53. PubMed ID: 19638454
    [Abstract] [Full Text] [Related]

  • 16. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE, Bochkova AG, Bunchuk NV.
    Ter Arkh; 2008 Oct; 80(5):25-30. PubMed ID: 18590110
    [Abstract] [Full Text] [Related]

  • 17. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N.
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [Abstract] [Full Text] [Related]

  • 18. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 19. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE.
    Arthritis Res Ther; 2006 May; 8(5):R151. PubMed ID: 16984661
    [Abstract] [Full Text] [Related]

  • 20. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.